VFA
ENTA icon

Virtus Fund Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

Virtus Fund Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1.03M Buy
+17,531
New +$878K 0.01% 282
2014
Q3 		– Sell
-882
Closed -$38K – 1382
2014
Q2 		$38K Buy
+882
New +$33.6K ﹤0.01% 2046

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Virtus Fund Advisers's ENTA Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Enanta Pharmaceuticals (ENTA) in Q4 2017: 17,531 shares worth $1.03M. The stake represents 0.01% of the portfolio and ranks #282 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in ENTA as recently as Q2 2014.

Virtus Fund Advisers first reported a position in ENTA in Q2 2014 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ENTA as of Q4 2017.

  • Virtus Fund Advisers held 17,531 shares of Enanta Pharmaceuticals worth $1.03M as of Q4 2017.
  • Enanta Pharmaceuticals was a new Virtus Fund Advisers position in Q4 2017.
  • Enanta Pharmaceuticals made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #282 holding.
  • Virtus Fund Advisers first reported a position in Enanta Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.